ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1121

Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies

Danlei Zhou1, Emily H King1, Simon Rothwell2, Olga Kryštůfková3, Antonella Notarnicola4, Samantha Coss1, Rabheh Abdul Aziz5, Katherine E Miller1, Amanda Dang1, G. Richard Yu1, Joanne Drew6, Emeli Lundstrom4, Lauren Pachman7, Gulnara Mamyrova8, Rodolfo V Curiel8, Boel De Paepe9, Jan De Bleecker9, Antony Payton10, William Ollier11, Terrance P O'Hanlon12, Ira Targoff12, Willy Flegel12, Vidya Sivaraman6, Edward Oberle6, Shoghik Akoghlanian6, Kyla Driest6, Charles H Spencer13, Yee Ling Wu14, Haikady N Nagaraja15, Stacy P Ardoin6, Hector Chinoy16, Lisa G Rider12, Frederick Miller12, Ingrid Lundberg17, Leonid Padyukov18, Jiří Vencovský3, Janine A Lamb2 and Chack-Yung Yu1, 1Center for Microbial Pathogenesis, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH, 2National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 5Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 6Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 7Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, 8Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, 9Department of Neurology, Ghent University Hospital, Ghent, Belgium, 10Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, 11Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom, 12Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, 13Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, 14Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, 15Division of Biostatistics, The Ohio State University, Columbus, OH, 16The University of Manchester, Sale, United Kingdom, 17Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 18Karolinska Institutet, Stockholm, Sweden

Meeting: ACR Convergence 2022

Keywords: Autoantibody(ies), autoimmune diseases, dermatomyositis, genetics, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Genetics, Genomics and Proteomics Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by autoantibodies plus infiltration of leukocytes into muscles and/or the skin, leading to destruction of blood vessels and muscle fibers, chronic muscle weakness and fatigue. While complement-mediated destruction of capillary endothelium in muscle and skin are implicated in juvenile and adult-onset dermatomyositis, the genetic contribution of complement C4 in IIM pathology remains unknown.

Methods: We elucidated the gene copy number (GCN) variations of total C4 (C4T), C4A and C4B, long and short genes in 1,644 Caucasian IIM patients, plus 3,526 matched healthy controls from the US and Europe using TaqMan-based realtime PCR or Southern blot analyses. Plasma complement protein levels were measured by single radial immunodiffusion.

Results: Low GCN of C4T (C4T=2+3) and C4A deficiency (C4A=0+1) were strong risk factors for IIM with odds ratios and 95% confidence intervals of 2.58 (2.28-2.91), p=5.0×10-53 for C4T; and 2.82 (2.48-3.21), p=7.0×10-57 for C4A deficiency. Contingency analyses showed that among patients with C4A deficiency, HLA-DRB1*03 became insignificant as a risk factor in IIM except for inclusion body myositis, in which 98.2% had HLA-DRB1*03 with an OR of 11.02 (1.44-84.4), p=0.0012. Multivariate logistic regression analyses were also performed for genetic risk factors of IIM and subgroups with healthy controls (Table 1). Predictors were chosen from results of individual analyses and added to logistic regression models. Those with p-values >0.05 were removed stepwise and those with p-value < 0.05 retained. In JDM and DM, C4A deficiency and C4 gene size were independent and significant risk factors. In PM and IBM, both HLA–DRB1*03 and C4 gene copy numbers were significant risk factors. In PM, HLA–DRB1*03 and C4A deficiency interacted to confer risk. In IBM, HLA–DRB1*03 was a very strong risk factor with contributions by continuous GCN variation of C4T. Intra-group analyses of IIM patients for C4 protein levels and IIM-related autoantibodies revealed that those with anti-Jo-1 or with anti-PM/Scl autoantibodies had significantly lower C4 concentrations than those without these autoantibodies.

Conclusion: In terms of genetic risk factors complement C4A deficiency was relevant for JDM and DM, while HLA-DR3 was important for IBM, and both C4A deficiency and HLA-DR3 contributed to PM.

Supporting image 1


Disclosures: D. Zhou, None; E. King, None; S. Rothwell, None; O. Kryštůfková, None; A. Notarnicola, None; S. Coss, None; R. Aziz, None; K. Miller, None; A. Dang, None; G. Yu, None; J. Drew, None; E. Lundstrom, None; L. Pachman, None; G. Mamyrova, Cure JM Foundation; R. Curiel, Bristol-Myers Squibb(BMS), Cure JM Foundation; B. Paepe, None; J. Bleecker, None; A. Payton, None; W. Ollier, None; T. O'Hanlon, None; I. Targoff, None; W. Flegel, None; V. Sivaraman, None; E. Oberle, None; S. Akoghlanian, None; K. Driest, None; C. Spencer, None; Y. Wu, None; H. Nagaraja, None; S. Ardoin, None; H. Chinoy, Eli Lilly, UCB; L. Rider, Hope Pharmaceuticals, Pfizer, Bristol-Myers Squibb(BMS); F. Miller, None; I. Lundberg, Argenx, AstraZeneca, Bristol Myers Squibb, Novartis, Corbus, EMD Serono, Roche, Pfizer, Orphazyme, Octapharma, Kezar, Janssen; L. Padyukov, None; J. Vencovský, Abbvie, Biogen, Boehringer, Eli Lilly, Gilead, Kezar, Merck, Novartis, Octapharma, Pfizer, Takeda, UCB, Werfen, Argenx; J. Lamb, None; C. Yu, None.

To cite this abstract in AMA style:

Zhou D, King E, Rothwell S, Kryštůfková O, Notarnicola A, Coss S, Aziz R, Miller K, Dang A, Yu G, Drew J, Lundstrom E, Pachman L, Mamyrova G, Curiel R, Paepe B, Bleecker J, Payton A, Ollier W, O'Hanlon T, Targoff I, Flegel W, Sivaraman V, Oberle E, Akoghlanian S, Driest K, Spencer C, Wu Y, Nagaraja H, Ardoin S, Chinoy H, Rider L, Miller F, Lundberg I, Padyukov L, Vencovský J, Lamb J, Yu C. Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/intricate-roles-of-low-gene-copy-numbers-for-complement-c4-c4a-deficiency-and-hla-drb103-as-genetic-risk-factors-for-myositis-its-subgroups-and-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/intricate-roles-of-low-gene-copy-numbers-for-complement-c4-c4a-deficiency-and-hla-drb103-as-genetic-risk-factors-for-myositis-its-subgroups-and-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology